Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subcutaneous anifrolumab in adults with moderate-to-severe systemic lupus erythematosus
2024-513031-24-00Phase 3Authorised
- Sponsor
- AstraZeneca
- Start
- Oct 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 17
01
Overview
Phase 3, randomised, double-blind trial in systemic lupus erythematosus (SLE) comparing Anifrolumab plus standard therapy with Placebo plus standard therapy (2 arms). Primary endpoint: BICLA response. Planned start Oct 2021; status: authorised.
02
Drugs
anifrolumab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on 2024-513031-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513031-24-00.